Measure In Vitro Cell Transduction (Infectivity)
Transducing cell lines with AAV-NanoLuc®-HaloTag® reporter for each AAV serotype allows you to measure the selectivity of each AAV serotype for the cell line transduced. If transduction is successful, the expressed NanoLuc® luciferase will produce a luminescent signal in the presence of a substrate. The resulting luminescent signal intensity is proportional to the transduction efficiency of AAV.
Detecting In Vivo Tropism and Biodistribution with NanoLuc® Luciferase
NanoLuc® luciferase and the Nano-Glo® Fluorofurimazine In Vivo Substrate (FFz) offer a new reporter option for AAV in vivo biodistribution studies. Optimized specifically for in vivo detection of NanoLuc® luciferase, the Nano-Glo® FFz Substrate is an aqueous soluble detection reagent with increased substrate bioavailability that leads to bright, stable signals. Nano-Glo® FFz has handling requirements compatible with in vivo workflows, offers flexible delivery options and the substrate specificity allows NanoLuc® and firefly luciferases to be used together for dual-luciferase imaging studies.
AAV Neutralizing Antibody (NAb) Assay
Neutralizing antibodies (anti-AAV antibodies) are present in the serum of human or animals previously exposed to AAV. The NanoLuc® luciferase-based NAb assay measures transduction inhibition of AAV resulting from the presence of anti-AAV antibodies in human serum. The antibodies block viral entry into the cells and prevent expression of NanoLuc® luciferase. Reduction in luminescent signal suggests that anti-AAV antibodies are present in the human serum.